tree sapling hand planting sprout in soil with sunset close up male hand planting young tree over green background

sarayut Thaneerat/Getty Images

Distressed & Defaults

Green shoots emerge in troubled European care-home sector

Staffing levels and occupancy rates in the European retirement and nursing home sector are normalizing, allowing some operators to start deleveraging.

Want to see more? Fill out the form below.

I agree to PitchBook’s privacy policy

The following analysis takes an in-depth look at the European retirement and nursing home sector, where strategic measures implemented by care-home operators are beginning to yield results.

Key points:

  • The situation in the European retirement and nursing home sector may not be as bleak as headlines suggest.
  • Staffing levels and occupancy rates are normalizing, helping some players to start deleveraging.
  • Colisée is in poor shape, but this operator was singled out by rating agencies in 2021 for its debt-funded acquisitions, while shareholder support was already viewed as key at the time.
  • While the sector may be investable, headline risk needs to be considered.

From some angles, the European retirement and nursing home sector appears to be embattled. Colisée, one of France’s leading pan-European operators, could be on the brink of a creditor takeover, while in Germany a steady stream of insolvencies (including for AWO, Argentum, and ESG Leer) shows no sign of abating.

Other names tell a different story, however. France’s Clariane and Emeis (formerly Orpea) — two heavyweights in the European nursing home sector — stated in their half-year results this summer that the “momentum” for their groups was positive, while Swedish-listed Attendo said it had one of its “strongest second quarters ever.”

“Operators are reporting continued improvement in occupancy rates year on year, returning to or already exceeding pre-pandemic levels, and fee uplifts from residents over the last year in previously struggling geographies such as France and Germany are improving profitability,” said Savills in its UK & European Care Home Investment report dated July 1, 2025, which is aimed at real estate investors. Observing that the share prices of Clariane and Emeis have been rebounding after years in the doldrums, Savills was cautiously optimistic: “This suggests a potential inflection point has been passed in the European Care Home sector, as two of the most severely affected businesses are beginning to recover strongly.”

Ratings upgrades
So, has the sector turned the corner? There are certainly green shoots — and, more importantly for credit investors, ratings upgrades.

Assessing the backdrop, this sector was hit by a perfect storm with the Covid pandemic and period of inflation that followed, explains Rémi Bringuier, lead analyst for Pharma and Healthcare Services at S&P Global Ratings. Moreover, the 2022 publication of The Gravediggers — a book by Victor Castanet which investigated standards and practices within French care homes (chiefly Orpea) and alleged mistreatment of residents — significantly eroded public trust and intensified scrutiny across the sector.

However, the tide appears to be turning. “The sector has been recovering steadily since 2024, evidenced by increasing sales, improving EBITDA margins, and gradual deleveraging across capital structures,” says Bringuier. This recovery prompted S&P to upgrade Domidep by one notch in June, and DomusVi (also by one notch) in July. Moody’s, meanwhile, upgraded Domidep in May, and changed DomusVi’s outlook to positive in June.

Encouraging signs are also emerging across the border in Germany. “While some German care-home operators are struggling with underperforming sites in less desirable areas, leading players with a stronger financial footing are expanding strategically — targeting top-tier properties in high-demand locations,” says Fabian Binoeder, managing director and healthcare expert at FTI Consulting’s Corporate Finance practice in Munich.

Key players
Care-home operators are diverse in their size, ownership structure and funding strategies. Some companies — such as Attendo, Clariane and Emeis — are listed, while others are privately owned including Germany’s third-largest operator Victor’s Group and leading UK player Barchester Healthcare, according to the Savills report. In addition, there are other firms in the sector that tap capital markets without a public rating, such as Germany’s Alloheim. All this means disclosure levels vary greatly from one company to another.

EUR CH table 1.png

According to French consultancy Planète Grise, Clariane was the largest operator in France at the end of 2024, but trailed Emeis on a Europe-wide basis.

EUR CH table 2.png

CLO exposure
According to Deutsche Bank, European CLOs maintained a stable exposure of €1.44 billion to DomusVi as of Sept. 12, which is unchanged since March. Within the healthcare sector, DomusVi stands as the sixth-largest obligor in European CLO portfolios. During the same period, exposure to Mehilainen (which is not a pure care-home player) rose to €1.44 billion, from €1.25 billion.

When looking at the top-25 CLO exposures across all sectors, Mehilainen is gaining ground, while HomeVi (DomusVi’s issuing vehicle) appears to be on a slight decline. Mehilainen was the sixteenth-largest obligor as of Sept. 8, representing 0.6% of European CLO portfolios and present in 69% of European CLOs, according to BofA Global Research. In July and August, Mehilainen ranked twenty-fourth on the same list.

DomusVi, meanwhile, was the eighteenth-largest exposure across sectors as a percentage of total CLO collateral (as of Sept. 8), having ranked fourteenth across July and August on the same basis, according to BofA. When measured by number of European CLOs that hold that name, DomusVi ranked twelfth in early September.

European CLOs’ exposure to Colisée amounted to €897.4 million in March, but European CLO managers have sought to get out of the name, selling €280 million year to date on a net basis (€323 million gross), according to a BofA Global Research report on Sept. 15. Only Altice France and Chrome Bidco (Cerba) saw larger volumes of sales in the year to date.

Meanwhile, European CLO exposure to Alloheim amounted to €374.9 million in March, according to DB’s data. Alloheim/Cidron Atrium SE’s E+500 facility B due May 2028 was listed in the downgrade section of Harvest CLO XXXI’s May 2025 investor report. The facility was also in the CCC obligations section of GoldenTree Loan Management EUR CLO 6’s June 2024 investor report, with a B- rating from S&P and an undisclosed rating in the Fitch column.

Downgrade for Colisée
Colisée was downgraded to selective default by S&P in May, after the care-home operator deferred the interest payment due April on its term loan B, which S&P viewed as tantamount to a default (S&P upgraded Colisée back to CCC- two days later). In June, Moody’s appended a limited default (LD) designation to Colisée Group’s probability of default rating, revising it to Ca-PD/LD, from Ca-PD.

S&P described Colisée’s capital structure as unsustainable, and forecast adjusted leverage (based on its own measure) of roughly 11.0x for 2024, compared with 9.2x in 2023, and the fixed-charge coverage ratio to fall below 1.0x to roughly 0.9x, from 1.23x a year earlier.

At the time, market participants expected EQT to inject €220 million of equity. Moody’s, in its June press release, said the company was “working with lenders to reinforce liquidity and address its capital structure, and the agreement to defer interest payment is a first step in this direction.”

This allowed the price of Colisée’s TLB to move back above 60. But during the summer, this scenario started to look increasingly unlikely. According to a source familiar with the situation, the most likely outcome now is a lender-led restructuring, with EQT handing over the keys.

EUR CH chart 1.png

Colisée had long been in the sights of rating agencies. Indeed, it only avoided S&P’s post-pandemic downgrades in 2023 because the agency had already downgraded the company to B- in 2021. In that 2021 downgrade release, S&P expressed concern over the pace of Colisée’s debt-funded acquisitions in the first quarter of the year. Moody’s highlighted a “more aggressive expansion strategy than initially anticipated,” but took comfort from the commitment to the business shown by shareholders EQT and CDPQ, and decided to affirm Colisée at B2.

According to Savills, Colisée is currently the second-largest care-homes operator in Belgium, the fourth-largest in France, and the fifth-largest in Spain.

Encouraging insights
While Colisée continues to cast a shadow over the market, recent earnings releases from other operators have offered encouraging insights.

In its first-half results published July 29, Clariane struck a positive chord — stating that access to funding was back to normal after an amendment and extension of its syndicated loan, the arrangement of a €775 million four-year real estate credit facility, and issuance of €400 million of unsecured bonds in June (which was more than three-times oversubscribed).

Clariane’s Wholeco leverage ratio has declined to 5.6x pro forma (adjusted for disposals for which proceeds have been received to date), from 5.8x pro forma (adjusted for capital increases) as of June 30, 2024. Clariane’s Wholeco leverage covenant combines corporate debt and real estate debt, and the company confirmed its target to reduce the Wholeco financial leverage ratio to below 5.5x at end-2025. Clariane’s RCF drawdown of €491 million was to be repaid in full on July 30, 2025. Net debt is expected to fall further in 2025.

AlphaValue equity analyst Yi Zhong sees “minimal risk” of Clariane missing its year-end leverage target. But Zhong also noted the group’s improved leverage was largely driven by the mid-June agreement to sell its Petits-fils network to Crédit Agricole Santé & Territoires for €345 million at a strong 14x EBITDA multiple, outperforming the 11–13x blended multiples achieved for other assets within Clariane’s €600 million secured disposal programme as of Q1. “It’s worth noting that Crédit Agricole Assurances remains Clariane’s largest anchor shareholder with a 26% stake,” AlphaValue recalled. “While the 14x multiple is impressive, its creditworthiness should be carefully evaluated given this relationship.”

Clariane is unrated, in contrast to DomusVi. When it upgraded the group’s holding company HomeVi to B, from B- in June, S&P said it expected HomeVi’s continuous improvement of its credit metrics in 2024 to continue in 2025, with adjusted leverage decreasing below 7.0x from 8.1x in 2023. Moody’s — which changed the outlook on the B3 rating to positive from stable in June — said it expects DomusVi to sustain a solid operating performance, leading to further improvement in key credit metrics over the next 12-18 months.

In its “MarketBeat Nursing Homes in Europe” 2025 report, Cushman & Wakefield highlighted the use of sale-and-leaseback deals by DomusVi to strengthen its finances. In the second half of 2024, Singapore’s Parkway Life REIT entered into the European market through the acquisition of nursing homes in France under a €111 million sale-and-leaseback arrangement with DomusVi. The portfolio consisted of 11 “premium assets,” DomusVi confirmed in a statement. “This major deal could potentially lead to future collaborations between Parkway Life and DomusVi,” C&W commented.

Parkway Life REIT invests in income-producing real estate and real estate-related assets that are used primarily for healthcare-related purposes. Until this deal with DomusVi, the Parkway REIT has focused on the Asia Pacific region.

In Spain, meanwhile, DomusVi closed a €92 million sale and leaseback in 2024 with Romano Senior (a company that was newly created by Azora Capital in collaboration with Banca March and Indosuez Wealth Management).

On the rebound
The rebound that’s taking shape in the sector stems from efforts by care-home operators themselves to strengthen balance sheets and reshape their operations, helped also by abating headwinds.

The lingering effects of the Covid pandemic — on staffing levels, patient intake, and operational costs — along with the surge in energy prices triggered by Russia’s invasion of Ukraine in 2022 are now easing, explains S&P’s Bringuier. At the same time, strategic measures implemented by care-home operators are beginning to yield results, contributing to an improvement in their fixed-charge coverage ratios, which is a key metric that’s closely monitored by rating agencies, he adds.

As the use of temporary (and more expensive) workers becomes less necessary and occupancy rates return to pre-Covid levels, the French care homes rated by S&P are now able to achieve EBITDA margins of 20-25%, approaching the 25-30% range seen before the pandemic, Bringuier notes.

In Germany, meanwhile, EBITDA margins can be as low as 2 to 3%, but the better-performing entities can achieve margins in the high single digits, estimates FTI’s Binoeder. Some German players, such as Alloheim, are working on their processes and seeking to streamline operations, while others — mostly state- and church-owned operators — are structurally less agile and struggle with underperforming assets, he points out.

In Binoeder’s view, care-home operators in Germany can still generate healthy returns despite regulatory pressures. However, those using opco/propco models are at a disadvantage, as rental costs weigh more heavily on their margins, he explains.

Germany’s care-home sector still has significant room for improvement, particularly in optimizing available resources and advancing digitalization, suggests Binoeder. Private groups — which are typically better positioned to implement such changes — stand to benefit most. However, he notes that certain bold reforms are often politically sensitive and therefore remain off the table.

Reputational factor
Care-home operators may be in better shape now than in 2022 and 2023, but investing in this sector is still not for the faint-hearted. Regulatory changes can impact the sector, notably in Germany where hospitals are going through a far-reaching reform process that may eventually impact care homes (which are positioned lower down the healthcare chain).

Reputational damage is also a key risk, and is sometimes mentioned in offering documentation. Accordingly, Clariane wrote in the docs of its recent bond deal that: “Due to the particularly sensitive nature of its care and health activities carried out by caregivers for vulnerable people, as well as the societal issues they represent, the Group may be exposed to risks of controversies.”

On Sept. 15, a group of top executives in the French healthcare system, including the CEOs of DomusVi and Emeis, published an article in French daily Le Figaro calling for an end to the vilification of the care-home sector, and urging all stakeholders to confront the urgent challenges posed by a rapidly ageing population and growing demand for long-term care.

Ultimately, the for-profit care-home sector will continue to face close scrutiny and remain exposed to significant headline risk, while standards of care remain deeply personal with expectations varying widely across individuals, concludes Bringuier.

sarayut Thaneerat/Getty Images

Learn about our editorial standards.